- NCIt
- C3708
Loading cancer entity…
Loading cancer entity…
Clinical trials
349 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04185038 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | recruiting | Phase 1 | 90 | Seattle Children's HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07498959 | Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer(TESTIGO) | recruiting | N/A | 160 | Sahlgrenska University HospitalOTHER | 1 |
| Mar 27, 2026 |
| clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04435756 | A Study of miRNA 371 in Patients With Germ Cell Tumors | active not recruiting | — | 956 | SWOG Cancer Research NetworkNETWORK | 3 | Mar 12, 2026 | clinicaltrials |
| NCT07463508 | Evaluation of Bile Acid Concentrations and Their Signaling as Markers of Testicular Tumorigenesis and Germ Cell Tumor Chemosensitivity(TG-BIL) | recruiting | N/A | 20 | University Hospital, Clermont-FerrandOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | active not recruiting | Phase 1 | 12 | Baylor College of MedicineOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07453082 | A Prospective Study to Evaluate miRNA371 and Outcomes in Patients With Newly Diagnosed Germ Cell Tumors(BRIDGE) | recruiting | — | 100 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06309745 | THERApy De-escalation for TESTicular Cancer(THERATEST) | recruiting | — | 30 | Queen Mary University of LondonOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07148050 | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells(IMPACT) | recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT02099734 | Germ Cell Tumor and Testicular Tumor DNA Registry | recruiting | — | 1,000 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04377932 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | active not recruiting | Phase 1 | 14 | Baylor College of MedicineOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03937843 | Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma | active not recruiting | Phase 2 | 135 | Swiss Cancer InstituteOTHER | 2 | Jan 20, 2026 | clinicaltrials |
| NCT04876456 | A Phase II Trial of Cabozantinib With Patients With Refractory GCTs | active not recruiting | Phase 2 | 50 | Jennifer KingOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05345158 | R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma | recruiting | N/A | 25 | University Health Network, TorontoOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT03500991 | HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors | active not recruiting | Phase 1 | 10 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05259605 | Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification | recruiting | — | 1,650 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Dec 17, 2025 | clinicaltrials |
| NCT02341989 | Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer(SWENOTECA-ABC) | active not recruiting | Phase 3 | 348 | St. Olavs HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05238883 | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 72 | HiFiBiO TherapeuticsINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT06937866 | Maintenance Zanzalintinib With Etoposide After HDCT in GCT | recruiting | Phase 1 / Phase 2 | 38 | Indiana UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT01453660 | Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls | active not recruiting | — | 44 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT00996710 | Genomic Structural Variation in Cancer Susceptibility | active not recruiting | — | 1,275 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT07224568 | Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors(INTERCEPT) | not yet recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06198296 | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | recruiting | Phase 1 | 21 | Baylor College of MedicineOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT05564026 | Molecular Epidemiology of Pediatric Germ Cell Tumors | recruiting | — | 1,151 | Children's Oncology GroupNETWORK | 1 | Oct 24, 2025 | clinicaltrials |
| NCT07199699 | Subxiphoid VATS for Giant Mediastinal Teratoma | not yet recruiting | N/A | 40 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT07188441 | Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin. | recruiting | Phase 2 | 40 | Chengcheng GuoOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT03418844 | Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy(VIVROVAIRE TR) | active not recruiting | N/A | 268 | Centre Francois BaclesseOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06133543 | Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer(RAISN) | recruiting | N/A | 44 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06144736 | PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND | recruiting | Phase 2 | 60 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04671693 | A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.(PASCA) | active not recruiting | N/A | 500 | Centre Leon BerardOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06418789 | High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors(GERMAN) | recruiting | Phase 2 | 25 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT05874063 | Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors(GIG-T) | recruiting | Phase 3 | 387 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT05142982 | Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma | recruiting | N/A | 74 | Tata Memorial CentreOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT04648462 | Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology | recruiting | — | 1,500 | Maastricht Radiation OncologyOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT05889585 | Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated with High-dose Chemotherapy and Autologous Stem Cell Transplant(HGT-QoL) | recruiting | N/A | 180 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT05836701 | Retrospective Study of Germ Cell Tumors of the Central Nervous System | active not recruiting | — | 500 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06421805 | Establishing Prospective Mediastinal Tumor Database of PUMCH(MTDPUMCH) | recruiting | — | 2,000 | Peking Union Medical College HospitalOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT06329323 | SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours(SUMMER) | not yet recruiting | — | 24 | Imperial College LondonOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT02429687 | TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors(MOGCT-01) | recruiting | Phase 3 | 129 | Beihua KongOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05670938 | Follow-up After Surgery for Testicular Cancer(FUTURE-testis) | recruiting | — | 145 | Erasmus Medical CenterOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT05672043 | Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China(GRIPP) | recruiting | — | 400 | Beijing Tiantan HospitalOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT05502224 | Multidisciplinary Approach to Fatigue | recruiting | N/A | 50 | Jules Bordet InstituteOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT04914026 | MicroRNA as Markers in Testicular Cancer | recruiting | — | 350 | Haukeland University HospitalOTHER | 2 | Aug 8, 2022 | clinicaltrials |
| NCT05455918 | Paclitaxel/Ifosfamide/Cisplatin Chemotherapy for High Risk Pediatric Germ Cell Tumor | recruiting | Phase 2 | 42 | Yonsei UniversityOTHER | 1 | Jul 13, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Apr 13, 2026source: clinicaltrials